NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment Into Two Sub-Studies

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198.… Read full story

NIH Scientists Discover How DNA Fragments Can Trigger Inflammation in Sickle Cell Disease

Researchers have discovered that DNA from the mitochondria – the cell’s “powerhouses” – acts as a danger signal in the body and triggers inflammation in people with sickle cell disease. A better understanding of mitochondrial DNA, long known to circulate in human blood, may provide vital insight into how to stop the underlying chronic inflammation that marks this inherited red blood cell disorder.… Read full story

Bravo Packing, Inc. Recalls All Performance Dog and Ground Beef Raw Pet Food Because of Possible Salmonella and Listeria Monocytogenes Health Risk to Humans and Animals

Bravo Packing, Inc. of Carneys Point, NJ is recalling all Ground Beef and Performance Dog, a frozen raw pet food because it has the potential to be contaminated with Salmonella and Listeria monocytogenes. Salmonella can cause illness in animals eating the products, as well as people who handle contaminated pet products, especially if they have not thoroughly washed their hands after having contact with the products, infected animals or any surfaces exposed to these products.  … Read full story

NIH Invests in Next Iteration of Public-Private Partnership to Advance Precision Medicine Research for Alzheimer’s Disease

The National Institutes of Health has launched the next version of the Accelerating Medicines Partnership (AMP) Alzheimer’s disease program (AMP AD 2.0) to expand the open science, big data approach for identifying biological targets for therapeutic intervention. AMP AD 2.0 is supporting new technologies, including cutting-edge, single-cell profiling and computational modeling, to enable a precision medicine approach to therapy development.… Read full story

NIH Effort Seeks to Understand MIS-C, Range of SARS-CoV-2 Effects on Children

The National Institutes of Health has launched a new research effort to understand how SARS-CoV-2, the virus that causes COVID-19, affects children, who account for roughly 13%(link is external) of the total cases of COVID-19 in the United States. The effort is called the Collaboration to Assess Risk and Identify Long-term Outcomes for Children with COVID (CARING for Children with COVID).… Read full story

Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Janssen COVID-19 Vaccine

February 27, 2021 – Today, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) to the Janssen Pharmaceuticals Companies of Johnson & Johnson for its single-shot COVID-19 vaccine, called Ad.26.COV2S or JNJ-78436725. The Janssen vaccine is a recombinant vector vaccine that uses a human adenovirus to express the spike protein found on the surface of the SARS-CoV-2 virus that causes COVID-19.… Read full story

Study Identifies Cardiovascular Risk Factors That May Lead to Pregnancy Problems for First-Time Moms

A new study of first-time pregnant women found risk factors for heart disease, such as obesity and elevated blood sugar, can put expectant moms at higher risk for pregnancy complications and gestational diabetes and also lead to increased chances of high blood pressure, or hypertension, two to seven years after giving birth.… Read full story